Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone and cognitive function in children with disruptive behavior disorders.

Gahan J Pandina1, Robert Bilder, Philip D Harvey

  • 1Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, New Jersey 08560, USA. gpandina@janus.jnj.com

Biological Psychiatry
|January 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.

Schizophrenia (Heidelberg, Germany)·2025
Same author

Applicability and Psychometric Properties of General Mental Health Assessment Tools in Autistic People: A Systematic Review.

Journal of autism and developmental disorders·2024
Same author

Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group.

Innovations in clinical neuroscience·2024
Same author

ADHD severity as a predictor of cognitive task performance in children with Autism Spectrum Disorder (ASD).

Research in developmental disabilities·2021
Same author

Executive Function in Autism: Association with ADHD and ASD Symptoms.

Journal of autism and developmental disorders·2021
Same author

Factor Structure of the Aberrant Behavior Checklist in Individuals with Fragile X Syndrome: Clarifications and Future Guidance.

Journal of child and adolescent psychopharmacology·2020

Risperidone did not negatively impact cognitive function in children with disruptive behavior disorders (DBDs) and below-average IQ. Long-term treatment maintained or improved attention and memory, suggesting age-appropriate development.

Area of Science:

  • Child and Adolescent Psychiatry
  • Neurodevelopmental Disorders
  • Pharmacological Interventions

Background:

  • Disruptive Behavior Disorders (DBDs) in children often co-occur with cognitive impairments.
  • Subaverage intelligence quotient (IQ) is a common comorbidity in children with DBDs.
  • Assessing the impact of psychotropic medications on cognitive function in this population is crucial.

Purpose of the Study:

  • To evaluate the effects of risperidone on cognitive function in children diagnosed with DBDs and subaverage IQ.
  • To determine if risperidone treatment alters attention and memory in this specific pediatric population.
  • To compare cognitive outcomes between risperidone and placebo groups.

Main Methods:

  • Combined data from two short-term (6-week) double-blind, placebo-controlled studies and three long-term (1-year) open-label studies.

Related Experiment Videos

  • Included 5- to 14-year-old patients with DBDs and subaverage IQ, treated with placebo or risperidone (0.02–0.06 mg/kg/day).
  • Utilized Continuous Performance Task (CPT) for attention and Verbal Learning Test for Children (VLT-C) for memory; assessed behavior with Nisonger Child Behavior Rating Form (NCBRF).

    • Main Results:

    • Risperidone significantly improved conduct problems compared to placebo in short-term studies and long-term studies.
    • No overall decline in cognitive function was observed; attention (CPT) and memory (VLT-C) showed significant improvements regardless of treatment in short-term studies.
    • Long-term risperidone treatment maintained or improved memory (VLT-C) and attention (CPT), with no adverse effect from sedation.

    Conclusions:

    • Risperidone did not negatively impact cognitive function in children with DBDs and subaverage IQ in the short term.
    • One year of risperidone treatment maintained or enhanced cognitive functions, including attention and memory.
    • Observed cognitive gains in children treated with risperidone may represent age-appropriate developmental progress.